
6th AnnualInvitation Only
AML-ALL
USFocus Meeting 2027
Three days, 74 people, one room.
July 8 to 10, 2027
San Diego, CA
Dates
July 8-10, 2027
Three-day program
Venue
San Diego, CA
Hotel TBC
Audience
74 by invitation
37 KOLs & 37 fellows
Format
10 sessions · 40 talks
Plenary, panels + case sessions
A Curated Room: The People Shaping Practice
This sixth annual, invitation-only meeting convenes a deliberately small faculty: 37 leading acute leukemia KOLs alongside 37 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for three days.
The science tracks where treatment is moving: menin inhibitors entering frontline combinations, FLT3 and IDH targeting across lines, HMA+VEN optimization, and bispecifics, ADCs and CAR-T reshaping relapsed and refractory disease. Every session pairs expert talks with a moderated panel, with case presentations threaded through both disease streams, sustained, close-quarters engagement rather than a lecture hall.
Menin InhibitorsFLT3 & IDH TargetingHMA+VEN OptimizationBispecifics, ADCs & CAR-TMRD-Guided StrategyAML · ALL · MDS
Meeting Co-Chairs
Listed alphabetically by surname

Naval Daver
MD Anderson Cancer Center, Houston, TX

Elias Jabbour
MD Anderson Cancer Center, Houston, TX
Faculty Drawn From
MD Anderson · Memorial Sloan Kettering · Dana-Farber · Moffitt · City of Hope and other leading US cancer centers
74
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
21
Established meetings across the US and Europe, a proven platform
AML-ALL US Focus Meeting 2027
Confirmed Faculty
Listed alphabetically by surname
Hussein Abbas
MD Anderson Cancer Center, Houston, TX
Ibrahim Aldoss
City of Hope, Duarte, CA
Roberta Azevedo
MD Anderson Cancer Center, Houston, TX
Kelly Chien
MD Anderson Cancer Center, Houston, TX
Naval Daver
MD Anderson Cancer Center, Houston, TX
Courtney DiNardo
MD Anderson Cancer Center, Houston, TX
Ann-Kathrin Eisfeld
OSU Comprehensive Cancer Center, Columbus, OH
Amir Fathi
Massachusetts General Hospital, Boston, MA
Armin Ghobadi
Washington University School of Medicine, St. Louis, MO
Sergio Giralt
Memorial Sloan Kettering Cancer Center, New York, NY
Hannah Goulart
MD Anderson Cancer Center, Houston, TX
Fadi Haddad
MD Anderson Cancer Center, Houston, TX
Christopher Hourigan
Virginia Tech FBRI Cancer Research Center, Washington, DC
Elias Jabbour
MD Anderson Cancer Center, Houston, TX
Nitin Jain
MD Anderson Cancer Center, Houston, TX
Tapan Kadia
MD Anderson Cancer Center, Houston, TX
Hagop Kantarjian
MD Anderson Cancer Center, Houston, TX
Rami Komrokji
Moffitt Cancer Center, Tampa, FL
Aaron Logan
UCSF Health, San Francisco, CA
Sanam Loghavi
MD Anderson Cancer Center, Houston, TX
Marlise Luskin
Dana-Farber Cancer Institute, Boston, MA
Susan O'Brien
UCI Health, Orange, CA
Kristen O'Dwyer
University of Rochester Medical Center, Rochester, NY
Jae Park
Memorial Sloan Kettering Cancer Center, New York, NY
Naveen Pemmaraju
MD Anderson Cancer Center, Houston, TX
Alexander Perl
University of Pennsylvania, Philadelphia, PA
Gail J. Roboz
Weill Cornell Medicine, New York, NY
David Sallman
Moffitt Cancer Center, Tampa, FL
Roland Walter
Fred Hutchinson Cancer Center, Seattle, WA
Eunice Wang
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Jun Yang
St. Jude Children's Research Hospital, Memphis, TN
Amer Zeidan
Yale School of Medicine, New Haven, CT
Joshua Zeidner
UNC School of Medicine, Chapel Hill, NC
Further faculty to be announced
Three Days, Ten Sessions
Proposed Agenda
Presentations15 min
Panel Discussions30 min
Lunch Break & Networking50 min
Day One · Thursday, July 8, 2027
Session ITBC
Moderator
Updates on CML
Hagop KantarjianMD Anderson Cancer Center, Houston, TX
Updates on CLL
Susan O'BrienUCI Health, Orange, CA
Updates on Low Risk MDS
Rami KomrokjiMoffitt Cancer Center, Tampa, FL
Panel Discussion
Session IITBC
Moderator
Updates on High Risk MDS
Speaker TBC
Updates on BPDCN
Naveen PemmarajuMD Anderson Cancer Center, Houston, TX
Case Presentations and Panel Discussion
Fadi Haddad (CML) and Kelly Chien (MDS)MD Anderson Cancer Center, Houston, TX
Panel Discussion & Take-Home Points From Day 1
Day Two · Friday, July 9, 2027
Session IIIPharmacogenomics and Treatment Effect
ModeratorTBC
Pharmacogenomics in ALL
Jun YangSt. Jude Children’s Research Hospital, Memphis, TN
How I Treat Philadelphia-Like ALL
Nitin JainMD Anderson Cancer Center, Houston, TX
How I Treat Ph+ ALL
Marlise LuskinDana-Farber Cancer Institute, Boston, MA
How I Treat Older ALL
Speaker TBC
Panel Discussion
Session IVTBC
ModeratorTBC
Updates From CAM: Genetic and Molecular Diagnostics in AML
Sanam LoghaviMD Anderson Cancer Center, Houston, TX
Optimization of Intensive Treatment Strategies in Non-FLT3m AML
Tapan KadiaMD Anderson Cancer Center, Houston, TX
Frontline Treatment of FLT3-ITD Mutated AML: Current Approaches and Future Directions
Alexander PerlUniversity of Pennsylvania, Philadelphia, PA
Optimizing Maintenance Approaches in Non-Transplanted Patients With AML
Gail J. RobozWeill Cornell Medicine, New York, NY
Optimizing Post-Transplant Maintenance Approaches and the ACT Platform Successes in SCT
Sergio GiraltMemorial Sloan Kettering Cancer Center, New York, NY
Panel Discussion
Lunch Break & Networking
Session VTBC
ModeratorTBC
Towards a Chemo-Free Regimen
Elias JabbourMD Anderson Cancer Center, Houston, TX
Updates on North America Cooperative Group Clinical Trials
Speaker TBC
CAR-T Consolidation in Frontline: Ready for Primetime
Jae ParkMemorial Sloan Kettering Cancer Center, New York, NY
How I Optimize Treatment of T-ALL: The Role of BH3 Mimetics
Kristen O'DwyerUniversity of Rochester Medical Center, Rochester, NY
Panel Discussion
Session VITBC
ModeratorTBC
AZA+VEN for All: What Is the Current Paradigm?
Amir FathiMassachusetts General Hospital, Boston, MA
FLT3 Triplets in AML: What More Is There to Say?
Naval DaverMD Anderson Cancer Center, Houston, TX
How Do I Use IDH Inhibitors in Frontline and R/R AML
Courtney DiNardoMD Anderson Cancer Center, Houston, TX
Selecting Optimal Treatments in R/R FLT3 AML and Understanding Mechanisms of Resistance
Speaker TBC
Using WES for Baseline Assessment and to Track MRD in New AML
Christopher HouriganVirginia Tech FBRI Cancer Research Center, Washington, DC
Panel Discussion
Special LectureFDA Perspectives on Endpoints in AML and Applications of MRD for AML Drug Development
Speaker TBC
Questions & Adjourn
Day Three · Saturday, July 10, 2027
Session VIITBC
Moderator
Novel Bispecific and ADC Therapies in ALL
Aaron LoganUCSF Health, San Francisco, CA
How Best to Sequence and Integrate Therapy in R/R ALL
Hagop KantarjianMD Anderson Cancer Center, Houston, TX
When Still to Transplant in ALL
Ibrahim AldossCity of Hope, Duarte, CA
When CAR-T Cells Therapies Should Be Considered a Destination Approach
Speaker TBC
Management of CNS Relapse
Speaker TBC
Panel Discussion
Session VIIITBC
ModeratorTBC
Frontline Fit NPM1 Mutated AML: What Is the “Best” Regimen?
Eunice WangRoswell Park Comprehensive Cancer Center, Buffalo, NY
Menin Inhibitors in R/R AML: Updates on Single Agent Menin Inhibitor Data Safety, Efficacy, Resistance
Speaker TBC
Frontline Menin Inhibitor Combos in Newly Diagnosed AML: Updates and Level Setting Expectations
Joshua ZeidnerUNC School of Medicine, Chapel Hill, NC
Panel Discussion
Lunch Break & Networking
Session IXTBC
Moderator
How to Manage ALL With Myeloid Mutation
Speaker TBC
Micro-Environment and Boosting T-Cell Response
Hussein AbbasMD Anderson Cancer Center, Houston, TX
CAR-T in T-Cell ALL
Armin GhobadiWashington University School of Medicine, St. Louis, MO
KMT2Ar Leukemia and Lineage Switch: Integration of Menin Inhibitors
Speaker TBC
Case Presentations in ALL and Panel Discussion
Hannah Goulart and Roberta AzevedoMD Anderson Cancer Center, Houston, TX
Panel Discussion
Session XTBC
ModeratorTBC
Understanding the Biology of RAS and Potential Mechanisms of Resistance to RAS Inhibitors in AML
Ann-Kathrin EisfeldOSU Comprehensive Cancer Center, Columbus, OH
CD33 and CD123 in AML: From GO to CD123, Has the Path Been Paved?
Roland WalterFred Hutchinson Cancer Center, Seattle, WA
Optimizing HMA+VEN Therapy in Frontline AML and Role of Oral HMA+VEN in AML
Amer ZeidanYale School of Medicine, New Haven, CT
Developing CARTs in AML: Current Status, Challenges, Emerging Constructs and Future Directions
David SallmanMoffitt Cancer Center, Tampa, FL
Panel Discussion & Take-Home Points
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →

Your Point of Contact
Zeynep Aydagül
Account Executive, MD Education
zeynep.aydagul@md-education.com
